ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

J Bousquet, P W Hellings, I Agache, A Bedbrook, C Bachert, K C Bergmann, M Bewick, C Bindslev-Jensen, S Bosnic-Anticevitch, C Bucca, D P Caimmi, P A M Camargos, G W Canonica, T Casale, N H Chavannes, A A Cruz, G De Carlo, R Dahl, P Demoly, P DevillierJ Fonseca, W J Fokkens, N A Guldemond, T Haahtela, M Illario, J Just, T Keil, L Klimek, P Kuna, D Larenas-Linnemann, M Morais-Almeida, J Mullol, R Murray, R Naclerio, R E O'Hehir, N G Papadopoulos, R Pawankar, P Potter, D Ryan, B Samolinski, H J Schunemann, A Sheikh, F E R Simons, M Barbagallo, F Blasi, M Bonini, M Cesari, A Fiocchi, G Iaccarino, A Romano

Research output: Contribution to journalReview article

64 Citations (Scopus)

Abstract

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.

Original languageEnglish
Pages (from-to)47
JournalClinical and Translational Allergy
Volume6
DOIs
Publication statusPublished - 2017

Fingerprint

Rhinitis
Life Cycle Stages
Asthma
Medicine
Technology
Clinical Decision Support Systems
Precision Medicine
Visual Analog Scale
Tablets
Allergic Rhinitis
Language
Economics
Guidelines
Morbidity
Delivery of Health Care
Physicians
Education
Health
Population

Cite this

ARIA 2016 : Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. / Bousquet, J; Hellings, P W; Agache, I; Bedbrook, A; Bachert, C; Bergmann, K C; Bewick, M; Bindslev-Jensen, C; Bosnic-Anticevitch, S; Bucca, C; Caimmi, D P; Camargos, P A M; Canonica, G W; Casale, T; Chavannes, N H; Cruz, A A; De Carlo, G; Dahl, R; Demoly, P; Devillier, P; Fonseca, J; Fokkens, W J; Guldemond, N A; Haahtela, T; Illario, M; Just, J; Keil, T; Klimek, L; Kuna, P; Larenas-Linnemann, D; Morais-Almeida, M; Mullol, J; Murray, R; Naclerio, R; O'Hehir, R E; Papadopoulos, N G; Pawankar, R; Potter, P; Ryan, D; Samolinski, B; Schunemann, H J; Sheikh, A; Simons, F E R; Barbagallo, M; Blasi, F; Bonini, M; Cesari, M; Fiocchi, A; Iaccarino, G; Romano, A.

In: Clinical and Translational Allergy, Vol. 6, 2017, p. 47.

Research output: Contribution to journalReview article

Bousquet, J, Hellings, PW, Agache, I, Bedbrook, A, Bachert, C, Bergmann, KC, Bewick, M, Bindslev-Jensen, C, Bosnic-Anticevitch, S, Bucca, C, Caimmi, DP, Camargos, PAM, Canonica, GW, Casale, T, Chavannes, NH, Cruz, AA, De Carlo, G, Dahl, R, Demoly, P, Devillier, P, Fonseca, J, Fokkens, WJ, Guldemond, NA, Haahtela, T, Illario, M, Just, J, Keil, T, Klimek, L, Kuna, P, Larenas-Linnemann, D, Morais-Almeida, M, Mullol, J, Murray, R, Naclerio, R, O'Hehir, RE, Papadopoulos, NG, Pawankar, R, Potter, P, Ryan, D, Samolinski, B, Schunemann, HJ, Sheikh, A, Simons, FER, Barbagallo, M, Blasi, F, Bonini, M, Cesari, M, Fiocchi, A, Iaccarino, G & Romano, A 2017, 'ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle', Clinical and Translational Allergy, vol. 6, pp. 47. https://doi.org/10.1186/s13601-016-0137-4
Bousquet, J ; Hellings, P W ; Agache, I ; Bedbrook, A ; Bachert, C ; Bergmann, K C ; Bewick, M ; Bindslev-Jensen, C ; Bosnic-Anticevitch, S ; Bucca, C ; Caimmi, D P ; Camargos, P A M ; Canonica, G W ; Casale, T ; Chavannes, N H ; Cruz, A A ; De Carlo, G ; Dahl, R ; Demoly, P ; Devillier, P ; Fonseca, J ; Fokkens, W J ; Guldemond, N A ; Haahtela, T ; Illario, M ; Just, J ; Keil, T ; Klimek, L ; Kuna, P ; Larenas-Linnemann, D ; Morais-Almeida, M ; Mullol, J ; Murray, R ; Naclerio, R ; O'Hehir, R E ; Papadopoulos, N G ; Pawankar, R ; Potter, P ; Ryan, D ; Samolinski, B ; Schunemann, H J ; Sheikh, A ; Simons, F E R ; Barbagallo, M ; Blasi, F ; Bonini, M ; Cesari, M ; Fiocchi, A ; Iaccarino, G ; Romano, A. / ARIA 2016 : Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. In: Clinical and Translational Allergy. 2017 ; Vol. 6. pp. 47.
@article{7291890ed86e42dca83ef2aa837861bd,
title = "ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle",
abstract = "The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.",
author = "J Bousquet and Hellings, {P W} and I Agache and A Bedbrook and C Bachert and Bergmann, {K C} and M Bewick and C Bindslev-Jensen and S Bosnic-Anticevitch and C Bucca and Caimmi, {D P} and Camargos, {P A M} and Canonica, {G W} and T Casale and Chavannes, {N H} and Cruz, {A A} and {De Carlo}, G and R Dahl and P Demoly and P Devillier and J Fonseca and Fokkens, {W J} and Guldemond, {N A} and T Haahtela and M Illario and J Just and T Keil and L Klimek and P Kuna and D Larenas-Linnemann and M Morais-Almeida and J Mullol and R Murray and R Naclerio and O'Hehir, {R E} and Papadopoulos, {N G} and R Pawankar and P Potter and D Ryan and B Samolinski and Schunemann, {H J} and A Sheikh and Simons, {F E R} and M Barbagallo and F Blasi and M Bonini and M Cesari and A Fiocchi and G Iaccarino and A Romano",
year = "2017",
doi = "10.1186/s13601-016-0137-4",
language = "English",
volume = "6",
pages = "47",
journal = "Clinical and Translational Allergy",
issn = "2045-7022",
publisher = "BioMed Central",

}

TY - JOUR

T1 - ARIA 2016

T2 - Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

AU - Bousquet, J

AU - Hellings, P W

AU - Agache, I

AU - Bedbrook, A

AU - Bachert, C

AU - Bergmann, K C

AU - Bewick, M

AU - Bindslev-Jensen, C

AU - Bosnic-Anticevitch, S

AU - Bucca, C

AU - Caimmi, D P

AU - Camargos, P A M

AU - Canonica, G W

AU - Casale, T

AU - Chavannes, N H

AU - Cruz, A A

AU - De Carlo, G

AU - Dahl, R

AU - Demoly, P

AU - Devillier, P

AU - Fonseca, J

AU - Fokkens, W J

AU - Guldemond, N A

AU - Haahtela, T

AU - Illario, M

AU - Just, J

AU - Keil, T

AU - Klimek, L

AU - Kuna, P

AU - Larenas-Linnemann, D

AU - Morais-Almeida, M

AU - Mullol, J

AU - Murray, R

AU - Naclerio, R

AU - O'Hehir, R E

AU - Papadopoulos, N G

AU - Pawankar, R

AU - Potter, P

AU - Ryan, D

AU - Samolinski, B

AU - Schunemann, H J

AU - Sheikh, A

AU - Simons, F E R

AU - Barbagallo, M

AU - Blasi, F

AU - Bonini, M

AU - Cesari, M

AU - Fiocchi, A

AU - Iaccarino, G

AU - Romano, A

PY - 2017

Y1 - 2017

N2 - The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.

AB - The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.

U2 - 10.1186/s13601-016-0137-4

DO - 10.1186/s13601-016-0137-4

M3 - Review article

C2 - 28050247

VL - 6

SP - 47

JO - Clinical and Translational Allergy

JF - Clinical and Translational Allergy

SN - 2045-7022

ER -